Kenneth Remy, MD

About

Kenneth E. Remy, MD, MHSc, MSCI, FCCM, is an NIH-funded physician-scientist and internationally recognized investigator in sepsis, critical illness, immune dysregulation, hemolysis biology and precision immunotherapy. He is The Ellery Sedgwick, Jr. Chair and Distinguished Scientist in Cardiovascular Research, Vice Chair of Medicine for Research Programs, and Associate Professor of Medicine, Pediatrics, Biochemistry, and Pathology and Immunology at Case Western Reserve University School of Medicine and University Hospitals of Cleveland. He is the founding Director of the Blood, Heart, Lung, and Immunology Research Center and leads adult and pediatric translational critical care research programs spanning mechanistic discovery, biomarker development, clinical investigation and multicenter trials.

Dr. Remy has developed a distinctive scientific program focused on understanding why patients with the same clinical syndrome of sepsis or critical illness develop profoundly different biologic responses. His laboratory investigates two interconnected areas. The first examines how intravascular hemolysis, cell-free hemoglobin and free heme alter vascular biology and reprogram innate and adaptive immunity in sepsis, transfusion, ECMO, malaria, sickle cell disease and other inflammatory disorders. In addition to helping establish hemolysis-derived products as active mediators of vascular injury and immune dysfunction rather than simply biomarkers of disease severity, his work has identified hemoglobin and heme trafficking pathways as potential therapeutic targets. The second major focus of his program is functional immune endotyping and precision immunotherapy.

Dr. Remy and his collaborators have helped demonstrate that sepsis and other forms of critical illness encompass biologically distinct immune states, including profound immune suppression. His laboratory helped develop and translate a rapid whole blood ELISpot platform that measures functional T cell and monocyte responses in near real time. This approach provides a practical framework for identifying immune competent and immune-suppressed patient populations, ultimately matching immunomodulatory therapies to the underlying biology of the individual patient.

During the COVID 19 pandemic, Dr. Remy became a prominent scientific and clinical leader in critical care and immunology. He cared for thousands of critically ill adult and pediatric patients while simultaneously redirecting his laboratory toward defining the hematologic and immune consequences of SARS-CoV-2 infection. Working with Richard Hotchkiss and other collaborators, his group was among the early investigators internationally to demonstrate profound T cell dysfunction, exhaustion and functional immune suppression in severe COVID 19, challenging the prevailing concept that critical disease represented a uniform cytokine storm. His research also examined immune restorative strategies, including IL 7 and signaling pathways relevant to targeted immunomodulatory therapy.

Dr. Remy has built a substantial independently funded research program. His current portfolio includes five NIH R level awards as Principal Investigator or Multiple Principal Investigator, including an NIGMS R35 MIRA, and he has secured more than 17 competitively funded federal, foundation and institutional awards across his career. His research spans mechanistic heme biology, pediatric sepsis endotyping, hemolysis and transfusion-related vascular injury, immune dysfunction and precision therapeutics. He has led or participated in more than 25 clinical and translational investigations and authored more than 150 peer-reviewed publications with an H-index of approximately 40.

Nationally and internationally, Dr. Remy serves in leadership roles in the Society of Critical Care Medicine, the Pediatric Acute Lung Injury and Sepsis Investigators Network, I SPY Sepsis and a number of international precision immunotherapy collaborations. He is also an established leader in global health and international critical care, with long-standing work in Latin America and Africa. In 2016, he co-founded the first post critical care fellowship in global health in Blantyre, Malawi, helping advance training, research and capacity building in resource-limited settings. He is an expert contributor to the Surviving Sepsis Campaign and contributed to the 2026 international guidelines for management of pediatric sepsis and septic shock. His work has been presented through more than 150 invited national and international lectures and visiting professorships.

Dr. Remy is also deeply committed to mentorship and the development of the next generation of physician-scientists. He has served as primary mentor for NIH K08 and K23 awardees and as a secondary mentor for multiple K12 scholars, while building multidisciplinary research programs that support junior investigators, fellows, residents, students and early-career faculty.

Dr. Remy received his medical degree from Jefferson Medical College, a Master of Health Sciences in clinical research from Duke University, and a Master of Science in clinical investigation with a focus on translational immunology from Washington University. He completed combined residency training in internal medicine and pediatrics at Case Western Reserve University School of Medicine and University Hospitals, fellowship training in pediatric critical care medicine at Columbia University and NewYork-Presbyterian Hospital, and fellowship and postdoctoral training in adult critical care medicine at the National Institutes of Health.

Dr. Remy’s career has been defined by a single translational objective: to understand the biologic heterogeneity of critical illness, identify the mechanisms that drive divergent immune responses, and translate those discoveries into precision diagnostics and individualized therapies for critically ill patients across the lifespan.